There are multiple first-line treatment options for patients with PD-L1+, EGFR/ALK-, non-squamous NSCLC including monotherapy targeting PD-1/PD-L1, as well as blockade of PD-1/PD-L1 in combination with chemotherapy or CTLA-4 blockade. Here, ALK is linked to non-small cell lung carcinoma.